Natera Stock Plummets After Mixed Q3 Financials
Natera Inc. (NTRA) reported Q3 revenue of $793.98M, beating estimates, but a loss of 42 cents per share, wider than expected. The company raised its 2026 revenue outlook to $3.01B-$3.04B. Test volumes grew 22.3%, with oncology testing up 60.9%. Solomon Moshkevich becomes CEO.
How this was made

The 30-second read
Why it matters
The earnings miss triggered a sharp stock decline, highlighting the market's focus on profitability over growth.
Market read
Natera's earnings surprise and leadership change are likely to drive short‑term trading activity in the biotech space.
What to watch
Cash position of $1.1 bn and expanding oncology test volumes may provide runway for profitability.
Background
Natera reported Q3 results with a revenue beat, a wider-than-expected loss, and raised full‑year guidance, while announcing a new CEO.
Ticker impact
Q3 earnings miss on loss per share despite revenue beat and raised 2026 guidance.
downward pressure as market prices in the wider loss per share.
Revenue beat is offset by a loss wider than expected, and the stock already plunged on the news.
Market effects
Genetic testing sector may see broader scrutiny of profit margins despite strong top‑line growth.
U.S. biotech stocks could see modest pullback as earnings miss spreads.
Limited to investors focused on U.S. biotech and precision‑medicine equities.
Counterpoint
Revenue acceleration and higher guidance could support a rebound if the loss narrows in future quarters.
Key entities
- companyNatera Inc.
Genetic testing firm reporting Q3 results.
- personSolomon Moshkevich
Newly appointed CEO of Natera.


